TVRD
Income statement / Annual
Last year (2025), Tvardi Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Tvardi Therapeutics Inc.'s net income was -$18.21 M.
See Tvardi Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$7.14 M |
$20.97 M |
$41.87 M |
$23.03 M |
$135.08 M |
| Cost of Revenue |
$95.00 K
|
$812.00 K
|
$6.43 M
|
$7.51 M
|
$1.55 M
|
$0.00
|
| Gross Profit |
-$95.00 K
|
$6.33 M
|
$14.54 M
|
$34.35 M
|
$21.47 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0.89
|
0.69
|
0.82
|
0.93
|
0
|
| Research and Development Expenses |
$18.01 M
|
$32.76 M
|
$108.38 M
|
$91.76 M
|
$82.58 M
|
$107.74 M
|
| General & Administrative Expenses |
$8.74 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.74 M
|
$26.39 M
|
$27.65 M
|
$30.13 M
|
$27.98 M
|
$20.94 M
|
| Other Expenses |
$0.00
|
$2.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.75 M
|
$62.11 M
|
$136.03 M
|
$121.89 M
|
$110.56 M
|
$128.68 M
|
| Cost And Expenses |
$26.75 M
|
$62.92 M
|
$142.46 M
|
$129.40 M
|
$112.11 M
|
$129.70 M
|
| Interest Income |
$1.38 M
|
$2.83 M
|
$1.32 M
|
$654.00 K
|
$603.00 K
|
$2.06 M
|
| Interest Expense |
$0.00
|
$8.47 M
|
$0.00
|
$3.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$95.00 K
|
$192.00 K
|
$259.00 K
|
$1.67 M
|
$1.55 M
|
$1.01 M
|
| EBITDA |
-$26.65 M |
-$62.60 M |
-$117.65 M |
-$83.80 M |
-$86.89 M |
$8.73 M |
| EBITDA Ratio |
0
|
-8.77
|
-5.61
|
-2
|
-3.77
|
0.06
|
| Operating Income Ratio |
0
|
-7.82
|
-5.79
|
-2.09
|
-3.87
|
0.04
|
| Total Other Income/Expenses Net |
$8.53 M
|
-$15.48 M
|
$2.98 M
|
$2.06 M
|
$642.00 K
|
$2.33 M
|
| Income Before Tax |
-$18.21 M
|
-$71.27 M
|
-$118.51 M
|
-$85.47 M
|
-$88.44 M
|
$7.72 M
|
| Income Before Tax Ratio |
0
|
-9.99
|
-5.65
|
-2.04
|
-3.84
|
0.06
|
| Income Tax Expense |
$0.00
|
-$398.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$691.00 K
|
| Net Income |
-$18.21 M
|
-$70.87 M
|
-$118.51 M
|
-$85.47 M
|
-$88.44 M
|
$8.41 M
|
| Net Income Ratio |
0
|
-9.93
|
-5.65
|
-2.04
|
-3.84
|
0.06
|
| EPS |
-2.46 |
-46.59 |
-1.85 |
-2.2 |
-62.77 |
6.39 |
| EPS Diluted |
-3.26 |
-46.59 |
-1.85 |
-2.2 |
-62.77 |
6.32 |
| Weighted Average Shares Out |
$7.42 M
|
$1.52 M
|
$9.36 M
|
$9.36 M
|
$1.41 M
|
$1.32 M
|
| Weighted Average Shares Out Diluted |
$7.78 M
|
$1.52 M
|
$9.36 M
|
$9.36 M
|
$1.41 M
|
$1.33 M
|
| Link |
|
|
|
|
|
|
